Genentech, announced the FDA has accepted the company�s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta (pertuzumab),...
Genentech/Roche announced that the FDA has approved Perjeta (pertuzumab). Perjeta is approved in combination with Herceptin (trastuzumab) and docetaxel chemotherapy...
NICE has issued draft guidance not recommending Perjeta (pertuzumab), from Roche, to treat HER2-positive breast cancer because it is uncertain...
The CHMP has given a positive opinion for the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel...
The EU has approved the use of Perjeta (pertuzumab), from Roche, in combination with Herceptin (trastuzumab) and chemotherapy for the...
Genentech announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab)...
Roche has announced that the European Medicines Agency (EMA) has approved Perjeta(pertuzumab) for patients with previously untreated HER2-positive metastatic Breast Cancer...
The CLEOPATRA study enrolled 808 patients with previously untreated HER2-positive metastatic breast cancer. Patients receiving Omnitarg (pertuzumab), from Genentech/Roche, on...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.